Carl Zeiss Meditec AG (AFX.F)
| Previous close | 97.60 |
| Open | 95.90 |
| Bid | 97.50 x 40000 |
| Ask | 98.30 x 40000 |
| Day's range | 95.90 - 96.90 |
| 52-week range | 73.18 - 124.35 |
| Volume | |
| Avg. volume | 327 |
| Market cap | 8.671B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | 31.26 |
| EPS (TTM) | 3.10 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | 1.10 (1.13%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 113.20 |
PR NewswireCarl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
Carl Zeiss Meditec AG announced today that, after securing all required regulatory approvals, it has completed the acquisition of 100% of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. The acquisition enhances and complements ZEISS Medical Technology's broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataract, glaucoma, and refracti
PR NewswireZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024
ZEISS Medical Technology will showcase the latest in 3D visualization technology and surgical innovation at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 5-8, 2024, in Boston, MA. Building on its ZEISS Medical Ecosystem, several of the new innovations enable seamless data integration and management across the cataract and refractive workflows, creating a new standard for efficient, personalized ophthalmic care.
Simply Wall St.Carl Zeiss Meditec's (ETR:AFX) investors will be pleased with their respectable 63% return over the last five years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
